ReviewOncotarget2012
Neoplastic cells are a rare component in human glioblastoma microvasculature.
Review in Oncotarget, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 85 citations in OpenAlex.
- Extracellular Vesicles in the Biology and Liquid Biopsy Diagnostics of Pediatric High-Grade Glioma - Emerging Findings and Opportunities.Journal of extracellular biology · 2026Review
- Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.Antioxidants & redox signaling · 2023Review
- On the origin and development of glioblastoma: multifaceted role of perivascular mesenchymal stromal cells.Acta neuropathologica communications · 2023Review
- Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance.Frontiers in physiology · 2023Review
- The diagnostic and prognostic potential of the EGFR/MUC4/MMP9 axis in glioma patients.Scientific reports · 2022Article
- Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms.Pharmaceutics · 2022Review
- Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade.Cancers · 2021Review
- In glioma, all endothelial cells are not created the same.Neuro-oncology · 2021Article
- Identification of diverse tumor endothelial cell populations in malignant glioma.Neuro-oncology · 2021Article
- Cancer Stem Cells and Neovascularization.Cells · 2021Review
- Three-DimensionalFrontiers in toxicology · 2021Review
- Tumor Endothelial Cell-A Biological Tool for Translational Cancer Research.International journal of molecular sciences · 2020Review
- Tumor angiogenesis: causes, consequences, challenges and opportunities.Cellular and molecular life sciences : CMLS · 2020Review
- Tumor Endothelial Heterogeneity in Cancer Progression.Cancers · 2019Review
- The Expression of Leptin and Its Receptor During Tumorigenesis of Diffuse Gliomas such as Astrocytoma and Oligodendroglioma- Grade II, III and IV (NOS)Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Laser Capture Microdissection and RNA-Seq Analysis: High Sensitivity Approaches to Explain Histopathological Heterogeneity in Human Glioblastoma FFPE Archived Tissues.Frontiers in oncology · 2019Article
- Endothelial trans-differentiation in glioblastoma recurring after radiotherapy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Glioma Stem Cell Niches in Human Glioblastoma Are Periarteriolar.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018Review
- IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme.Oncotarget · 2018Article
- Multiscale modeling of glioblastoma.Translational cancer research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Microvascular proliferation is a key biological and diagnostic hallmark of human glioblastoma, one of the most aggressive forms of human cancer. It has recently been suggested that stem-like glioblastoma cells have the capacity to differentiate into functional endothelial cells, and that a significant proportion of the vascular lining in tumors has a neoplastic origin. In principle, this finding could significantly impact the efficacy and development of antiangiogenic therapies targeting the vasculature. While the potential of stem-like cancer cells to form endothelium in culture seems clear, in our clinical experience using a variety of molecular markers, neoplastic cells do not contribute significantly to the endothelial-lined vasculature of primary human glioblastoma. We sought to confirm this impression by analyzing vessels in glioblastoma previously examined using chromogenic in situ hybridization (CISH) for EGFR and immunohistochemistry for mutant IDH1. Vessels containing cells expressing these definitive neoplastic markers were identified in a small fraction of tumors, but only 10% of vessel profiles examined contained such cells and when identified these cells comprised less than 10% of the vascular cellularity in the cross section. Interestingly, these rare intravascular cells showing EGFR amplification by CISH or mutant IDH1 protein by immunohistochemistry were located in the middle or outer portions of vessel walls, but not amongst the morphologic boundaries of the endothelial lining. To more directly address the capacity of glioblastoma cells to contribute to the vascular endothelium, we performed double labeling (Immunofluorescence/FISH) for the endothelial marker CD34 and EGFR gene locus. This analysis did not identify EGFR amplified CD34+ endothelial cells within vascular linings, and further supports our observation that incorporation of glioblastoma cells into the tumor vessels is, at best, extremely rare of questionable clinical or therapeutic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.